Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New NSAIDs and gastroduodenal damage

G C Folco1

  • 1Istituto di Scienze Farmacologiche, Università di Milano, Italy.

The Italian Journal of Gastroenterology
|December 1, 1996
PubMed
Summary

Selective cyclooxygenase-2 (COX-2) inhibitors offer anti-inflammatory benefits without the gastrointestinal side-effects associated with traditional non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-1.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The pulmonary pharmacology of [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide] (2NTX-99), an anti-atherotrombotic compound with therapeutic potential in pathological conditions that target lung vasculature.

Prostaglandins & other lipid mediators·2012
Same author

Antagonism of thromboxane receptors by diclofenac and lumiracoxib.

British journal of pharmacology·2007
Same author

A new class of nitric oxide-releasing derivatives of cetirizine; pharmacological profile in vascular and airway smooth muscle preparations.

British journal of pharmacology·2007
Same author

Evaluation of the pharmacological activity of the pure cysteinyl-leukotriene receptor antagonists CGP 45715A (iralukast) and CGP 57698 in human airways.

Advances in experimental medicine and biology·2000
Same author

Inhibition of prostanoid synthesis protects against neuronal damage induced by focal ischemia in rat brain.

Neuroscience letters·1998
Same author

Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro.

British journal of pharmacology·1998

Area of Science:

  • Biochemistry
  • Pharmacology
  • Gastroenterology

Background:

  • Cyclooxygenase (COX) exists in two isoforms: COX-1 (constitutive) and COX-2 (inducible).
  • COX-2 is upregulated by inflammatory stimuli, correlating with prostaglandin production in inflammatory sites.
  • Existing non-steroidal anti-inflammatory drugs (NSAIDs) inhibit both COX isoforms, leading to significant gastrointestinal side-effects.

Purpose of the Study:

  • To evaluate the efficacy and safety of selective COX-2 inhibitors.
  • To compare the therapeutic profile of COX-2 inhibitors with non-selective NSAIDs.

Main Methods:

  • Review of existing literature on COX-1 and COX-2 enzyme functions.
  • Analysis of clinical data comparing selective COX-2 inhibitors with non-selective NSAIDs.
  • Assessment of prostaglandin synthesis inhibition in inflammatory cells.

Main Results:

  • Selective COX-2 inhibitors demonstrate comparable anti-inflammatory activity to non-selective NSAIDs.
  • COX-2 inhibitors effectively inhibit prostaglandin synthesis in inflammatory cells.
  • Unlike non-selective NSAIDs, selective COX-2 inhibitors do not induce gastric or intestinal ulcers.

Conclusions:

  • Selective COX-2 inhibition provides a safer alternative for managing inflammatory conditions.
  • Targeting COX-2 specifically avoids the adverse gastrointestinal effects linked to COX-1 inhibition.

Related Experiment Videos